Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a ...

Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before ...

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

Exelixis reported increased revenue and earnings in Q4 2024, driven by strong cabozantinib sales, though competitive ...

Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which ...

Exelixis (EXEL) announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating Cabometyx in combination with Opdivo versus ...

(RTTNews) - Exelixis, Inc. (EXEL) Thursday announced that its Board of Directors has authorized an additional $500 million stock repurchase program, set to run through December 31. The company ...

Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. See why I ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Citi 2025 ...

TD Cowen raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps a Buy rating on the shares. The firm said they posted a ...

Exelixis (NASDAQ:EXEL – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued on Wednesday.